DBV Technologies | Passività Correnti



Current Liabilities Cambiamento Data
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
Alnylam Pharmaceuticals USD 1.19B 34.39M 2024-12
Amarin USD 201.55M 28.99M 2024-09
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
DBV Technologies USD 30.91M 3.53M 2024-09
Halozyme Therapeutics USD 139.1M 30.28M 2024-12
Incyte USD 1.64B 140.2M 2024-12
Insmed USD 297.53M 38.34M 2024-12
Ionis Pharmaceuticals USD 309.32M 4.75M 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
PTC Therapeutics USD 580.98M 29.73M 2024-12
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
United Therapeutics USD 738.1M 135.3M 2024-12



DBV Technologies Passività Correnti - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Apr 2025.